About Selecta Biosciences (NASDAQ:SELB)
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis. It is also developing SEL-403 product candidate, a combination therapy comprising SVP-rapamycin and LMB-100, which is in Phase I clinical trial for the treatment of patients with malignant pleural or peritoneal mesothelioma; and SELA-070, a nicotine vaccine product candidate that is in Phase I clinical trial for smoking cessation and relapse prevention. In addition, the company engages in the development of gene therapy product candidates that are in preclinical development for rare inborn errors of metabolism, including SEL-302, a lead gene therapy program for the treatment methylmalonic academia; and SEL-313, a gene therapy product candidate to treat ornithine transcarbamylase deficiency. Selecta Biosciences, Inc. has license and collaboration agreements with Spark Therapeutics, Massachusetts Institute of Technology, Shenyang Sunshine Pharmaceutical Co., Ltd., BIND Therapeutics, Inc., and Massachusetts Eye and Ear Infirmary, as well as research collaboration agreements with National Cancer Institute. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SELB
CUSIPN/A
Phone617-923-1400
Debt
Debt-to-Equity Ratio0.41%
Current Ratio9.00%
Quick Ratio9.00%
Price-To-Earnings
Trailing P/E Ratio-4.03
Forward P/E Ratio-3.80
P/E GrowthN/A
Sales & Book Value
Annual Sales$210,000.00
Price / Sales1,325.04
Cash FlowN/A
Price / CashN/A
Book Value$2.32 per share
Price / Book5.37
Profitability
EPS (Most Recent Fiscal Year)($3.20)
Net Income$-65,320,000.00
Net Margins-31,556.04%
Return on Equity-110.64%
Return on Assets-65.05%
Miscellaneous
Employees64
Outstanding Shares22,350,000
Selecta Biosciences (NASDAQ:SELB) Frequently Asked Questions
What is Selecta Biosciences' stock symbol?
Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."
How were Selecta Biosciences' earnings last quarter?
Selecta Biosciences Inc. (NASDAQ:SELB) released its earnings results on Thursday, March, 15th. The company reported ($0.88) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.56) by $0.32. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $15 million. Selecta Biosciences had a negative net margin of 31,556.04% and a negative return on equity of 110.64%. View Selecta Biosciences' Earnings History.
What price target have analysts set for SELB?
3 equities research analysts have issued 1 year target prices for Selecta Biosciences' stock. Their predictions range from $30.00 to $30.00. On average, they anticipate Selecta Biosciences' stock price to reach $30.00 in the next twelve months. View Analyst Ratings for Selecta Biosciences.
What are Wall Street analysts saying about Selecta Biosciences stock?
Here are some recent quotes from research analysts about Selecta Biosciences stock:
- 1. Mizuho analysts commented, "We believe the expected phase 3 trial including 6 monthly combination doses of SEL-212 has a high likelihood of success." (4/11/2018)
- 2. According to Zacks Investment Research, "Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. " (3/21/2018)
- 3. Canaccord Genuity analysts commented, "We expect the combination dosing to provide rapid, sustained SUA lowering similarly to what has been seen for the combination SEL-212 + SVP dosing in the ongoing Phase 2 trial." (1/18/2018)
Who are some of Selecta Biosciences' key competitors?
Some companies that are related to Selecta Biosciences include Keryx Biopharmaceuticals (KERX), Aclaris Therapeutics (ACRS), TiGenix - American Depositary Shares (TIG), Dicerna Pharmaceuticals (DRNA), ChemoCentryx (CCXI), Akebia Therapeutics (AKBA), Achaogen (AKAO), Progenics Pharmaceuticals (PGNX), Achillion Pharmaceuticals (ACHN), AC Immune (ACIU), StemlineTherapeutics (STML), Clementia Pharmaceuticals (CMTA), Insys Therapeutics (INSY), MediciNova (MNOV), ObsEva (OBSV), Zealand Pharma (ZEAL), Concert Pharmaceuticals (CNCE) and Sinovac Biotech (SVA).
Who are Selecta Biosciences' key executives?
Selecta Biosciences' management team includes the folowing people:
- Dr. Omid C. Farokhzad, Co-Founder, Chairman & Member of the Scientific Advisory Board (Age 49)
- Dr. Werner Cautreels, Pres, CEO & Director (Age 65)
- Mr. Peter Keller, Consultant (Age 47)
- Mr. Earl Sands M.D., Chief Medical Officer (Age 60)
- Dr. Ulrich H. von Andrian-Werburg M.D., Ph.D., Co-Founder and Co-Chair of the Scientific Advisory Board
When did Selecta Biosciences IPO?
(SELB) raised $64 million in an initial public offering on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.
Has Selecta Biosciences been receiving favorable news coverage?
News headlines about SELB stock have trended somewhat positive on Thursday, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Selecta Biosciences earned a coverage optimism score of 0.23 on Accern's scale. They also gave news coverage about the company an impact score of 46.10 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of Selecta Biosciences?
Shares of SELB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Selecta Biosciences' stock price today?
One share of SELB stock can currently be purchased for approximately $12.45.
How big of a company is Selecta Biosciences?
Selecta Biosciences has a market capitalization of $288.31 million and generates $210,000.00 in revenue each year. The company earns $-65,320,000.00 in net income (profit) each year or ($3.20) on an earnings per share basis. Selecta Biosciences employs 64 workers across the globe.
How can I contact Selecta Biosciences?
Selecta Biosciences' mailing address is 480 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-923-1400 or via email at [email protected]
MarketBeat Community Rating for Selecta Biosciences (SELB)
MarketBeat's community ratings are surveys of what our community members think about Selecta Biosciences and other stocks. Vote "Outperform" if you believe SELB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SELB will underperform the S&P 500 over the long term. You may vote once every thirty days.
Selecta Biosciences (NASDAQ:SELB) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Selecta Biosciences in the last 12 months. Their average twelve-month price target is $30.00, suggesting that the stock has a possible upside of 140.96%. The high price target for SELB is $30.00 and the low price target for SELB is $30.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.67 | 2.75 | 2.67 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $30.00 | $28.50 | $28.00 | $29.00 |
| Price Target Upside: | 140.96% upside | 218.79% upside | 200.11% upside | 30.16% upside |
Selecta Biosciences (NASDAQ:SELB) Consensus Price Target History
Selecta Biosciences (NASDAQ:SELB) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
Selecta Biosciences (NASDAQ:SELB) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Selecta Biosciences (NASDAQ SELB) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 41.90%
Institutional Ownership Percentage: 50.15%
Selecta Biosciences (NASDAQ SELB) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/17/2017 | Earl Sands | Insider | Buy | 7,500 | $10.26 | $76,950.00 | 7,500 |  |
| 11/14/2017 | Timothy A Springer | Director | Buy | 57,598 | $9.27 | $533,933.46 | 461,349 | |
| 11/13/2017 | Werner Cautreels | Insider | Buy | 20,000 | $9.31 | $186,200.00 | 321,203 | |
| 11/10/2017 | Timothy C Barabe | Director | Buy | 5,000 | $9.37 | $46,850.00 | 4,992 | |
| 9/26/2017 | Amir Nashat | Director | Sell | 70,226 | $18.91 | $1,327,973.66 | | |
| 9/25/2017 | Amir Nashat | Director | Sell | 79,211 | $19.13 | $1,515,306.43 | | |
| 9/21/2017 | Amir Nashat | Director | Sell | 147,187 | $19.91 | $2,930,493.17 | | |
| 9/20/2017 | Amir Nashat | Director | Sell | 42,610 | $20.03 | $853,478.30 | | |
| 9/20/2017 | David Siewers | CFO | Sell | 16,424 | $20.00 | $328,480.00 | 2,194 | |
| 7/3/2017 | Lloyd P Johnston | COO | Sell | 5,959 | $19.10 | $113,816.90 | 7,565 | |
| 6/30/2017 | David Siewers | CFO | Sell | 7,420 | $20.00 | $148,400.00 | 7,420 | |
| 6/29/2017 | David Siewers | CFO | Sell | 9,652 | $20.00 | $193,040.00 | 3,882 | |
| 6/27/2017 | Peter Keller | Insider | Sell | 4,595 | $19.30 | $88,683.50 | 5,000 | |
| 6/27/2017 | Timothy A Springer | Director | Buy | 338,791 | $17.71 | $5,999,988.61 | 355,413 | |
| 6/26/2017 | David Siewers | CFO | Sell | 6,886 | $20.00 | $137,720.00 | 36 | |
| 6/15/2017 | Lloyd P Johnston | COO | Sell | 20,512 | $17.00 | $348,704.00 | 22,118 | |
| 6/1/2017 | Timothy A Springer | Director | Buy | 518 | $13.75 | $7,122.50 | 16,622 | |
| 5/18/2017 | Timothy A Springer | Director | Buy | 16,104 | $14.00 | $225,456.00 | 11,244 | |
| 5/16/2017 | Edwin M. Kania, Jr. | Director | Sell | 266,795 | $14.00 | $3,735,130.00 | | |
| 4/17/2017 | Lloyd P Johnston | COO | Sell | 13,205 | $13.95 | $184,209.75 | 14,811 | |
| 12/28/2016 | Takashi Kei Kishimoto | Insider | Sell | 10,000 | $17.55 | $175,500.00 | 10,000 | |
| 12/21/2016 | David Abraham | Insider | Sell | 14,844 | $18.00 | $267,192.00 | 14,844 | |
| 12/19/2016 | Peter Keller | Insider | Sell | 4,723 | $18.58 | $87,753.34 | | |
| 6/27/2016 | Amir Nashat | Director | Buy | 150,000 | $14.00 | $2,100,000.00 | | |
| 6/27/2016 | Nanodimension Management Ltd | Major Shareholder | Buy | 385,000 | $14.00 | $5,390,000.00 | | |
(Data available from 1/1/2013 forward)
Selecta Biosciences (NASDAQ SELB) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | An Upcoming Drug May Emerge as the Winner in the War on Chronic Severe Gout
247wallst.com - April 17 at 4:46 PM |
 | Selecta Biosciences Inc. (SELB) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 17 at 1:32 AM |
| Selecta Biosciences (SELB) Given a $25.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - April 15 at 8:22 PM |
 | 6 Biotech and Medtech Stocks That Saw Massive Moves This Week
www.msn.com - April 14 at 9:19 AM |
 | MYND Excited, STDY Steadying Up, SELB Awaits Data In Q3, EYPT Catches Eyes
www.nasdaq.com - April 13 at 9:30 AM |
 | Edited Transcript of SELB conference call or presentation 10-Apr-18 12:30pm GMT
finance.yahoo.com - April 12 at 10:03 AM |
 | Selecta Biosciences (SELB) Presents On New SEL-212 Phase 2 Data
seekingalpha.com - April 11 at 4:39 PM |
| Selecta Biosciences (SELB) Receives Buy Rating from Mizuho
www.americanbankingnews.com - April 11 at 8:59 AM |
| Selecta Biosciences under pressure after new data on gout candidate SEL-212, shares down 10%
seekingalpha.com - April 10 at 4:40 PM |
| Selecta Biosciences Sinks Despite Positive Midstage Data
www.msn.com - April 10 at 4:40 PM |
| Selecta Biosciences Presents Positive New Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at PANLAR 2018 Congress
finance.yahoo.com - April 10 at 9:29 AM |
| Selecta Biosciences (SELB) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - April 8 at 7:34 PM |
| An Ear To The Pharma: 9 Stocks To Watch This Week (SELB, AGLE, BPMC, MNOV…)
www.nasdaq.com - April 8 at 8:59 AM |
 | The Week Ahead In Biotech: PDUFA Dates, IPOs And More
feeds.benzinga.com - April 6 at 1:37 PM |
| Selecta Biosciences to Present Updated Clinical Phase 2 Data of Lead Candidate SEL-212 at the Pan American League of Associations for Rheumatology (PANLAR) Congress on April 10, 2018
finance.yahoo.com - April 3 at 9:26 AM |
| Where Selecta Biosciences Inc’s (NASDAQ:SELB) Earnings Growth Stands Against Its Industry
finance.yahoo.com - March 31 at 9:06 AM |
| Selecta Biosciences (SELB) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - March 31 at 6:52 AM |
| Contrasting Selecta Biosciences (SELB) and Voyager Therapeutics (VYGR)
www.americanbankingnews.com - March 30 at 5:18 PM |
| Selecta Biosciences (SELB) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 29 at 1:56 PM |
| Financial Exchange Stock Talk: Joe McCann On Selecta Biosciences
seekingalpha.com - March 28 at 9:10 AM |
| Selecta Biosciences Inc (SELB) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 23 at 1:32 AM |
| Zacks Investment Research Lowers Selecta Biosciences (SELB) to Strong Sell
www.americanbankingnews.com - March 21 at 1:57 PM |
| Selecta Biosciences to Present at the Needham Healthcare Conference on March 27, 2018
finance.yahoo.com - March 20 at 4:49 PM |
| Edited Transcript of SELB earnings conference call or presentation 15-Mar-18 12:30pm GMT
finance.yahoo.com - March 18 at 9:39 AM |
| Selecta Biosciences (SELB) Upgraded to "Strong-Buy" by BidaskClub
www.americanbankingnews.com - March 17 at 4:28 PM |
| When Will Selecta Biosciences Inc (NASDAQ:SELB) Breakeven?
finance.yahoo.com - March 16 at 10:04 AM |
| Selecta Biosciences (SELB) Releases Earnings Results, Misses Estimates By $0.32 EPS
www.americanbankingnews.com - March 16 at 9:44 AM |
| Selecta Biosciences Announces Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 15 at 10:19 AM |
| Selecta Biosciences Announces Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 15 at 10:19 AM |
| Selecta Biosciences Announces First Patient Dosed in Phase 1 Trial of SVP-Rapamycin and LMB-100 Combination Therapy in Mesothelioma
finance.yahoo.com - March 12 at 4:44 PM |
| Selecta Biosciences to Report Fourth Quarter and Year End 2017 Financial Results on Thursday, March 15, 2018
finance.yahoo.com - March 8 at 10:31 AM |
| Analyzing Selecta Biosciences (SELB) & Catalyst Pharmaceuticals (CPRX)
www.americanbankingnews.com - March 7 at 11:17 AM |
| Selecta Biosciences Inc (SELB) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 26 at 5:08 PM |
| Selecta Biosciences (SELB) Coverage Initiated by Analysts at Mizuho
www.americanbankingnews.com - February 26 at 4:20 PM |
| Selecta Biosciences (SELB) Downgraded to Strong Sell at ValuEngine
www.americanbankingnews.com - February 4 at 1:48 PM |
| Selecta Biosciences (SELB) Rating Reiterated by Canaccord Genuity
www.americanbankingnews.com - January 19 at 12:58 AM |
| Analyzing Selecta Biosciences (SELB) & Its Rivals
www.americanbankingnews.com - January 16 at 9:26 PM |
| Comparing Selecta Biosciences (SELB) and Its Rivals
www.americanbankingnews.com - January 16 at 3:10 AM |
| Publication Authored by Researchers at Selecta Biosciences and the National Cancer Institute in Proceedings of the National Academy of Sciences (PNAS) Discusses Restoration of Anti-Tumor Activity of Recombinant Immunotoxin LMB-100 When Combined with SVP-Rapamycin
finance.yahoo.com - January 9 at 10:38 AM |
| Reviewing Selecta Biosciences (SELB) and Its Rivals
www.americanbankingnews.com - January 6 at 11:52 AM |
| Selecta Biosciences Inc (NASDAQ:SELB): What’s The Analyst Consensus Outlook?
finance.yahoo.com - January 5 at 6:25 PM |
| Selecta Biosciences Announces CEO’s Intent to Retire and Transition Plan
finance.yahoo.com - January 2 at 10:36 AM |
| Selecta Biosciences Inc’s (NASDAQ:SELB) Earnings Declined 44.7%, But How Did It Fare Against The Industry?
finance.yahoo.com - December 28 at 1:44 PM |
| ETFs with exposure to Selecta Biosciences, Inc. : December 27, 2017
finance.yahoo.com - December 27 at 4:32 PM |
| Selecta Biosciences, Inc. :SELB-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017
finance.yahoo.com - December 26 at 11:20 AM |
| Head-To-Head Review: Selecta Biosciences (SELB) and Its Peers
www.americanbankingnews.com - December 18 at 7:50 AM |
| Achillion Pharmaceuticals (ACHN) & Selecta Biosciences (SELB) Critical Comparison
www.americanbankingnews.com - November 29 at 7:30 AM |
| Selecta Biosciences, Inc. (SELB) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - November 27 at 5:50 PM |
| Earl Sands Purchases 7,500 Shares of Selecta Biosciences, Inc. (SELB) Stock
www.americanbankingnews.com - November 21 at 4:41 PM |
| Insider Buying: Selecta Biosciences, Inc. (SELB) Director Purchases 57,598 Shares of Stock
www.americanbankingnews.com - November 16 at 8:10 PM |
Selecta Biosciences (NASDAQ:SELB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Selecta Biosciences (NASDAQ:SELB) Income Statement, Balance Sheet and Cash Flow Statement
Selecta Biosciences (NASDAQ SELB) Stock Chart for Thursday, April, 19, 2018
Loading chart…
